Amgen’s obesity drug MariTide has shown promising results in a Phase 2 clinical trial, helping participants lose up to one-fifth of their body weight. The drug, which is taken monthly, combines a GLP-1 receptor agonist with a monoclonal antibody. The results, published in The New England Journal of Medicine and presented at the American Diabetes Association’s 85th Scientific Sessions, also indicate significant improvements in blood glucose levels and heart disease risk factors.
Full Story: NBC News (6/23)